Aurinia Pharmaceuticals Ownership | Who Owns Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals Ownership Summary
Aurinia Pharmaceuticals is owned by 0.23% institutional investors, 9.84% insiders, and 89.94% retail investors. Blackrock is the largest institutional shareholder, holding 6.44% of AUPH shares. iShares Russell 2000 ETF is the top mutual fund, with 2.14% of its assets in Aurinia Pharmaceuticals shares.
AUPH Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Aurinia Pharmaceuticals | 0.23% | 9.84% | 89.94% |
Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock | 9.27M | 6.44% | $52.94M |
Blackrock funding, inc. /de | 8.95M | 6.26% | $80.39M |
Tang capital management | 8.43M | 5.89% | $75.70M |
Armistice capital | 6.40M | 4.47% | $57.47M |
Nea management company | 3.97M | 2.78% | $35.65M |
State street | 2.92M | 2.04% | $26.20M |
Geode capital management | 1.76M | 1.23% | $15.84M |
Goldman sachs group | 1.75M | 1.22% | $15.73M |
Vanguard group | 1.73M | 1.21% | $15.53M |
Nuveen asset management | 1.49M | 1.04% | $13.40M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Tang capital management | 8.43M | 5.01% | $75.70M |
Nea management company | 3.97M | 2.01% | $35.65M |
Armistice capital | 6.40M | 0.78% | $57.47M |
Virtus investment advisers | 82.83K | 0.58% | $743.79K |
Ironwood investment management | 94.31K | 0.42% | $846.90K |
Pdt partners | 301.55K | 0.24% | $2.71M |
Virtus fund advisers | 7.03K | 0.20% | $63.15K |
Highmark wealth management | 21.70K | 0.11% | $194.83K |
Sunbelt securities | 160.22K | 0.09% | $914.88K |
Ifp advisors | 271.13K | 0.08% | $2.43M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Tang capital management | 8.43M | 5.01% | 1.20M |
Arrowstreet capital, limited partnership | 1.08M | 0.01% | 1.08M |
Blackrock | 9.27M | 0.00% | 609.18K |
Lazard asset management | 596.39K | 0.01% | 461.43K |
Jpmorgan chase | 927.30K | 0.00% | 424.48K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Armistice capital | 6.40M | 0.78% | -1.80M |
Rock springs capital management lp | - | - | -1.18M |
Schroder investment management group | - | - | -997.22K |
Point72 asset management | - | - | -849.62K |
Goldman sachs group | 1.75M | 0.00% | -655.85K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Arrowstreet capital, limited partnership | 1.08M | 0.01% | 1.08M | $9.66M |
Qube research | 195.76K | 0.00% | 195.76K | $1.76M |
Squarepoint ops | 116.60K | 0.00% | 116.60K | $1.05M |
Norges bank | 114.05K | 0.00% | 114.05K | $651.20K |
Wellington management group llp | 60.75K | 0.00% | 60.75K | $545.54K |
Sold Out
Holder | Change |
---|---|
Vima | -25.00 |
Nelson, van denburg & campbell wealth management group | -26.00 |
Federation des caisses desjardins du quebec | -40.00 |
Parallel advisors | -43.00 |
Stephens consulting | -45.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 3 | -98.60% | 312,556 | -99.46% | - | 0.01% | 1 | -99.00% | - | -100.00% |
Dec 31, 2024 | 210 | 6.60% | 57,561,302 | -0.09% | 40 | 2.48% | 98 | 16.67% | 49 | 11.36% |
Sep 30, 2024 | 195 | 7.73% | 57,393,945 | 3.76% | 40 | 2.69% | 83 | -2.35% | 43 | - |
Jun 30, 2024 | 180 | -8.63% | 55,314,751 | 0.64% | 38 | 2.61% | 85 | 13.33% | 42 | -32.26% |
Mar 31, 2024 | 197 | -6.19% | 54,961,177 | 3.27% | 38 | 2.78% | 75 | -9.64% | 62 | 1.64% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
iShares Russell 2000 ETF | 2.81M | 2.14% | -53.45K |
Fidelity Small Cap Index | 1.36M | 1.03% | -241.00 |
iShares Russell 2000 Growth ETF | 1.04M | 0.79% | - |
State St Russell Sm/Mid Cp® Indx SL Cl I | 833.00K | 0.63% | - |
State St Russell Sm/Mid Cp® Indx NL Cl C | 820.80K | 0.60% | - |
iShares Biotechnology ETF | 742.01K | 0.56% | 6.34K |
Vanguard Russell 2000 ETF | 599.73K | 0.46% | -77.24K |
Lazard US Sm Cap Eq WW Dist EUR | 577.32K | 0.43% | 58.09K |
International Biotechnology Ord | 534.69K | 0.41% | - |
Vanguard Explorer Inv | 425.41K | 0.31% | 134.96K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Aug 05, 2025 | TANG KEVIN | - | Buy | $2.34M |
Aug 01, 2025 | TANG KEVIN | - | Buy | $10.12M |
Aug 04, 2025 | TANG KEVIN | - | Buy | $1.13M |
Aug 01, 2025 | Keenan Greg | Chief Medical Officer | Sell | $210.00K |
Mar 07, 2025 | Keenan Greg | Chief Medical Officer | Sell | $68.35K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q3 | 3 | 1 |
2025 Q2 | - | - |
2025 Q1 | 6 | 10 |
2024 Q4 | 3 | 2 |
2024 Q3 | - | 1 |
AUPH Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools